[go: up one dir, main page]

PE20090822A1 - DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE - Google Patents

DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE

Info

Publication number
PE20090822A1
PE20090822A1 PE2008000994A PE2008000994A PE20090822A1 PE 20090822 A1 PE20090822 A1 PE 20090822A1 PE 2008000994 A PE2008000994 A PE 2008000994A PE 2008000994 A PE2008000994 A PE 2008000994A PE 20090822 A1 PE20090822 A1 PE 20090822A1
Authority
PE
Peru
Prior art keywords
androst
cyano
ona
eno
derivative
Prior art date
Application number
PE2008000994A
Other languages
English (en)
Inventor
Joachim Kuhnke
Jan Huebner
Rolf Bohlmann
Thomas Frenzel
Ulrich Klar
Frederik Menges
Sven Ring
Steffen Borden
Hans-Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20090822A1 publication Critical patent/PE20090822A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE Z ES O, NOH, NNHSO2H, ENTRE OTROS; R4 ES H, HALOGENO; R6a Y R6b JUNTOS FORMAN METILENO, 1,2-ETANODIILO, ENTRE OTROS; R7 ES H, METILO; R9 Y R10 SON CADA UNO H, FORMAN UN ENLACE DOBLE; R15 Y R16 SON CADA UNO H, O JUNTOS FORMAN METILENO; R17 ES H, ALILO, ALQUILO C1-C4. SON COMPUESTOS PREFERIDOS: 17BETA-CIANO-6-BETA-HIDROXIMETILEN-19-NOR-ANDROST-4-EN-3-ONA; 17ALFA-ALILO-17 BETA-CIANO-19-NOR-ANDROST-4-EN-3-ONA; 17BETA-IANO-17ALFA-METIL-6ALFA,7ALFA-METILEN-19-NOR-ANDROST-4-EN-3-ONA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON SON UTILES EN EL TRATAMIENTO DE TRASTORNOS PRE-,PERI- Y POSMENOPAUSICOS Y TRASTORNOS PREMENSTRUALES
PE2008000994A 2007-06-12 2008-06-11 DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE PE20090822A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007027637A DE102007027637A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PE20090822A1 true PE20090822A1 (es) 2009-07-25

Family

ID=39986163

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000994A PE20090822A1 (es) 2007-06-12 2008-06-11 DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE

Country Status (20)

Country Link
US (1) US8207150B2 (es)
EP (1) EP2170925B1 (es)
JP (1) JP2010529153A (es)
KR (1) KR20100028554A (es)
CN (1) CN101679478A (es)
AR (1) AR066971A1 (es)
AU (1) AU2008261278A1 (es)
BR (1) BRPI0813937A2 (es)
CA (1) CA2690959A1 (es)
DE (1) DE102007027637A1 (es)
ES (1) ES2397996T3 (es)
IL (1) IL202359A0 (es)
MX (1) MX2009013629A (es)
PA (1) PA8784401A1 (es)
PE (1) PE20090822A1 (es)
RU (1) RU2010100331A (es)
TW (1) TW200909444A (es)
UY (1) UY31146A1 (es)
WO (1) WO2008151746A2 (es)
ZA (1) ZA201000187B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
CN104530165A (zh) * 2014-12-10 2015-04-22 浙江仙琚制药股份有限公司 制备4,9-双烯物的方法
CN105085596A (zh) * 2015-08-18 2015-11-25 湖北竹溪人福药业有限责任公司 一种羧酸黄体酮的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3579509A (en) * 1965-06-21 1971-05-18 Smith Kline French Lab Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids
GB1089945A (en) * 1965-09-23 1967-11-08 British Drug Houses Ltd Steroidal-6-spirocyclopropyl-4-en-3-ones
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
FR2139708B1 (es) * 1971-06-01 1974-08-23 Roussel Uclaf
BE795241A (fr) 1972-02-11 1973-08-09 Schering Ag 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation
DE2456068A1 (de) 1974-11-23 1976-08-12 Schering Ag Verfahren zur herstellung von oestren3,17-dion-derivaten
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4252800A (en) * 1979-10-05 1981-02-24 United States Of America 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DD281394A5 (de) * 1984-12-10 1990-08-08 Jenapharm Veb Verfahren zur herstellung von steroid-c-17 alpha-carbonitrilen
DD281393A5 (de) * 1984-12-10 1990-08-08 Jenapharm Veb Verfahren zur herstellung von steroid-c-17 beta-carbonitrilen
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP2170925A2 (de) 2010-04-07
KR20100028554A (ko) 2010-03-12
PA8784401A1 (es) 2009-01-23
ES2397996T3 (es) 2013-03-13
BRPI0813937A2 (pt) 2014-12-30
EP2170925B1 (de) 2012-10-24
WO2008151746A3 (de) 2009-03-12
DE102007027637A1 (de) 2008-12-18
MX2009013629A (es) 2010-01-20
TW200909444A (en) 2009-03-01
RU2010100331A (ru) 2011-07-20
IL202359A0 (en) 2010-06-30
JP2010529153A (ja) 2010-08-26
AU2008261278A1 (en) 2008-12-18
US20090048217A1 (en) 2009-02-19
US8207150B2 (en) 2012-06-26
ZA201000187B (en) 2011-03-30
WO2008151746A2 (de) 2008-12-18
UY31146A1 (es) 2009-01-30
CA2690959A1 (en) 2008-12-18
AR066971A1 (es) 2009-09-23
CN101679478A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
PE20090312A1 (es) DERIVADO DE 17 -CIANO-18a-HOMO-19-NOR-ANDROST-4-ENO
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
PA8591701A1 (es) Derivados de pirrolopirimidina
ECSP099371A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
PE20090822A1 (es) DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
SE0403171D0 (sv) New compounds
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
PE20140792A1 (es) Composiciones farmaceuticas
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal